These results demonstrate significant tumor growth restriction of Tras-resistant HER2+ tumors with Tras IgE treatment, indicating Fc-mediated immune functions in the absence of direct Fab-mediated effects in vivo. The gene discussed is IGHE; the disease is neoplasm.